Literature DB >> 26910586

Identifying a maximum tolerated contour in two-dimensional dose finding.

Nolan A Wages1.   

Abstract

The majority of phase I methods for multi-agent trials have focused on identifying a single maximum tolerated dose combination (MTDC) among those being investigated. Some published methods in the area have been based on the notion that there is no unique MTDC and that the set of dose combinations with acceptable toxicity forms an equivalence contour in two dimensions. Therefore, it may be of interest to find multiple MTDCs for further testing for efficacy in a phase II setting. In this paper, we present a new dose-finding method that extends the continual reassessment method to account for the location of multiple MTDCs. Operating characteristics are demonstrated through simulation studies and are compared with existing methodology. Some brief discussion of implementation and available software is also provided.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  dose finding; drug combination; equivalence contour; phase I

Mesh:

Substances:

Year:  2016        PMID: 26910586      PMCID: PMC4993696          DOI: 10.1002/sim.6918

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  24 in total

1.  Continual reassessment methods in phase I trials of the combination of two drugs in oncology.

Authors:  A Kramar; A Lebecq; E Candalh
Journal:  Stat Med       Date:  1999-07-30       Impact factor: 2.373

2.  Two-dimensional dose finding in discrete dose space.

Authors:  Kai Wang; Anastasia Ivanova
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  Sequential continual reassessment method for two-dimensional dose finding.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Stat Med       Date:  2008-11-29       Impact factor: 2.373

4.  A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.

Authors:  Akihiro Hirakawa; Chikuma Hamada; Shigeyuki Matsui
Journal:  Stat Med       Date:  2013-05-06       Impact factor: 2.373

5.  Phase I trial design for drug combinations with Bayesian model averaging.

Authors:  Ick Hoon Jin; Lin Huo; Guosheng Yin; Ying Yuan
Journal:  Pharm Stat       Date:  2015-01-13       Impact factor: 1.894

6.  Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Authors:  Leena Gandhi; Rastislav Bahleda; Sara M Tolaney; Eunice L Kwak; James M Cleary; Shuchi S Pandya; Antoine Hollebecque; Richat Abbas; Revathi Ananthakrishnan; Anna Berkenblit; Mizue Krygowski; Yali Liang; Kathleen W Turnbull; Geoffrey I Shapiro; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

7.  Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Authors:  Kenneth H Mayer; Salim Abdool Karim; Clifton Kelly; Lisa Maslankowski; Helen Rees; Albert T Profy; Jennifer Day; Julie Welch; Zeda Rosenberg
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

8.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

9.  Bridging Solutions in Dose Finding Problems.

Authors:  John O'Quigley; Alexia Iasonos
Journal:  Stat Biopharm Res       Date:  2014-05-01       Impact factor: 1.452

Review 10.  Adaptive designs for dual-agent phase I dose-escalation studies.

Authors:  Jennifer A Harrington; Graham M Wheeler; Michael J Sweeting; Adrian P Mander; Duncan I Jodrell
Journal:  Nat Rev Clin Oncol       Date:  2013-03-19       Impact factor: 66.675

View more
  5 in total

1.  Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2016-11-07       Impact factor: 1.864

2.  AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.

Authors:  Jiaying Lyu; Yuan Ji; Naiqing Zhao; Daniel V T Catenacci
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-13       Impact factor: 1.864

3.  A design for phase I trials in completely or partially ordered groups.

Authors:  Mark R Conaway
Journal:  Stat Med       Date:  2017-04-06       Impact factor: 2.373

4.  Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.

Authors:  Mourad Tighiouart
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2018-06-22       Impact factor: 1.680

5.  Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.

Authors:  Márcio Augusto Diniz; Mourad Tighiouart
Journal:  J Biom Biostat       Date:  2017-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.